A Prospective Study on the Diagnosis of Malignant Tumors With 18F-FGIn PET/CT

Recruiting now

Conditions studied: Cancer (With or Without Metastasis)

In brief

Glutamine is a crucial nutrient for cancer cell growth, and its metabolism is frequently dysregulated in malignancies. 18F-FGln is a PET tracer that targets this altered glutamine metabolism. However, there are currently limited studies on the diagnostic value of 18F-FGln PET/CT in various types of cancer. Therefore, this prospective study was conducted to investigate the value of 18F-FGln PET/CT in patients with various types of malignant tumors.

Key facts

Study ID
NCT07602569
Run by
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
People needed
110
Starts
2025-10-20
Expected to finish
2028-12-01
Last updated by the study team
2026-05-22

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.